“Our goal was to educate these patients thoroughly on the risks and benefits of each of these therapies, and try to understand what guides their choice of third line therapy based on their lifestyle and what suits them,” says Anjali Kapur, MD.
In this video, Anjali Kapur, MD, and Jason Kim, MD, discuss the background and findings of the study, “Patient preference of third line therapy for overactive bladder,” which will be presented at the Society of Women in Urology Annual Clinical Mentoring Conference. Kapur is a PGY-4 resident and Kim is an associate professor of urology, director of the Women’s Pelvic Health and Continence Center, and urology residency program director at Stony Brook Medicine in East Setauket, New York.
Optimizing outcomes in sacral neuromodulation for overactive bladder
October 11th 2023These findings may help guide decision-making in the initial testing phase of the [sacral neuromodulation] device prior to permanent implant or explant, according to Bradley Gill, MD, of the Cleveland Clinic.